Published in Leukemia on February 01, 2005
The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders. Hematol Oncol (2010) 1.67
Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. Blood (2006) 1.18
Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents. Biologics (2008) 1.06
Neutral evolution in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (2008) 1.05
Animal models for acquired bone marrow failure syndromes. Clin Med Res (2005) 1.03
Clonotype analysis of cytomegalovirus-specific cytotoxic T lymphocytes. J Am Soc Nephrol (2008) 0.88
Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches. Haematologica (2009) 0.86
A paroxysmal nocturnal haemoglobinuria progress with waldenström macroglobulinemia along with T cell monoclonal expansion. Indian J Hematol Blood Transfus (2014) 0.75
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99
Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med (1994) 4.86
Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science (1993) 4.12
5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med (1982) 3.29
A human parvovirus-like virus inhibits haematopoietic colony formation in vitro. Nature (1983) 3.02
Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med (1987) 2.93
SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia (2011) 2.82
Gram-negative sepsis: detection of endotoxemia with the limulus test. With studies of associated changes in blood coagulation, serum lipids, and complement. Ann Intern Med (1972) 2.79
High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet (2000) 2.75
An invertebrate coagulation system activated by endotoxin: evidence for enzymatic mediation. J Clin Invest (1972) 2.61
Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc Natl Acad Sci U S A (1991) 2.55
Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood (2000) 2.42
Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci U S A (1985) 2.33
Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology (1996) 2.26
Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med (1999) 2.17
Improving prognosis following a first variceal haemorrhage over four decades. Gut (2001) 2.14
Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest (1989) 2.08
Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia (2010) 2.01
Strand displacement amplification and homogeneous real-time detection incorporated in a second-generation DNA probe system, BDProbeTecET. Clin Chem (1999) 2.01
Hepatitis-associated aplastic anemia. N Engl J Med (1997) 1.98
Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glycoprotein. Virology (1996) 1.97
Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet (1988) 1.97
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol (1999) 1.97
Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood (1995) 1.91
Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood (2001) 1.89
Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med (1989) 1.85
Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia (2013) 1.84
Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector. Proc Natl Acad Sci U S A (1992) 1.82
Characterization of a virus that causes transient aplastic crisis. J Clin Invest (1984) 1.78
Infection of hematopoietic progenitor cells by human cytomegalovirus. Blood (1992) 1.76
Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol (1993) 1.76
Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells. Blood (1994) 1.75
Dengue virus, a flavivirus, propagates in human bone marrow progenitors and hematopoietic cell lines. Blood (1989) 1.69
Immunologic abnormalities in patients receiving multiple blood transfusions. Ann Intern Med (1984) 1.66
Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nat Med (1995) 1.65
Clinical relevance of parvovirus B19 as a cause of anemia in patients with human immunodeficiency virus infection. J Infect Dis (1997) 1.63
Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. J Clin Invest (1992) 1.63
Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia. Br J Haematol (1989) 1.56
Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood (1996) 1.56
Correction of the PNH defect by GPI-anchored protein transfer. Blood (1998) 1.55
Low drug attributability of aplastic anemia in Thailand. The Aplastic Anemia Study Group. Blood (1997) 1.55
Treatment of Diamond-Blackfan anaemia with haematopoietic growth factors, granulocyte-macrophage colony stimulating factor and interleukin 3: sustained remissions following IL-3. Br J Haematol (1991) 1.50
A block in full-length transcript maturation in cells nonpermissive for B19 parvovirus. J Virol (1992) 1.48
Decreased plasma cytokines are associated with low platelet counts in aplastic anemia and immune thrombocytopenic purpura. J Thromb Haemost (2012) 1.47
Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood (1999) 1.47
Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med (1994) 1.45
Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J Virol (1993) 1.45
Circulating activated suppressor T lymphocytes in aplastic anemia. N Engl J Med (1985) 1.43
Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood (1986) 1.42
UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation. Leukemia (2008) 1.39
Fanconi anemia and novel strategies for therapy. Blood (1994) 1.39
Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector. J Clin Invest (1994) 1.39
The structure of human parvovirus B19 at 8 A resolution. Virology (1994) 1.38
Interferon is the suppressor of hematopoiesis generated by stimulated lymphocytes in vitro. J Immunol (1984) 1.38
Association of seropositivity for hepatitis viruses and aplastic anemia in Thailand. Hepatology (1997) 1.38
Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes. Leukemia (2007) 1.37
Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol (1995) 1.33
Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood (1996) 1.32
Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia (2012) 1.31
A putative nucleoside triphosphate-binding domain in the nonstructural protein of B19 parvovirus is required for cytotoxicity. J Virol (1994) 1.30
Cryo-electron microscopy studies of empty capsids of human parvovirus B19 complexed with its cellular receptor. Proc Natl Acad Sci U S A (1996) 1.29
Recombinant adeno-associated virus (rAAV)-mediated expression of a human gamma-globin gene in human progenitor-derived erythroid cells. Proc Natl Acad Sci U S A (1994) 1.28
Molecular, cellular and clinical aspects of parvovirus B19 infection. Crit Rev Oncol Hematol (1994) 1.28
Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC). Hum Gene Ther (1999) 1.28
Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br J Haematol (1995) 1.27
gamma-Interferon gene expression in the bone marrow of patients with aplastic anemia. Ann Intern Med (1994) 1.26
Identification of a novel simian parvovirus in cynomolgus monkeys with severe anemia. A paradigm of human B19 parvovirus infection. J Clin Invest (1994) 1.26
Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore) (1992) 1.25
Limited heterogeneity of T cell receptor BV usage in aplastic anemia. J Clin Invest (2001) 1.25
Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood (2001) 1.24
A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia. Blood (1996) 1.24
Spread of human cytomegalovirus (HCMV) after infection of human hematopoietic progenitor cells: model of HCMV latency. Blood (1997) 1.24
Studies of interferon as a regulator of hematopoietic cell proliferation. J Immunol (1985) 1.23
TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia (2009) 1.23
Infection of mononucleated phagocytes with human cytomegalovirus. Virology (1993) 1.23
A genetically engineered cell line that produces empty capsids of B19 (human) parvovirus. Proc Natl Acad Sci U S A (1989) 1.22
First continuous propagation of B19 parvovirus in a cell line. Blood (1992) 1.22
Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia. Leukemia (2011) 1.21
The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis (1986) 1.20
Neither human immunodeficiency virus-1 (HIV-1) nor HIV-2 infects most-primitive human hematopoietic stem cells as assessed in long-term bone marrow cultures. Blood (1998) 1.19
Single nucleotide polymorphism arrays complement metaphase cytogenetics in detection of new chromosomal lesions in MDS. Leukemia (2007) 1.19
Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol (1997) 1.17